Frontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based Therapies Offer Strong Potential in Difficult-To-Treat Subtypes

  • ID: 3843310
  • Report
  • Region: Global
  • 68 pages
  • GBI Research
1 of 5
Chronic Pain Treatment Pipeline Could Yield Innovative Alternatives to Opioids
Pain is a complex and multifaceted disorder with a complex interplay between different pathological processes, and different pain subtypes exhibiting distinct underlying etiologies and patho-physiologies. While technological advances and extensive research efforts have furthered the understanding of the pathophysiology of these complex indications, substantial gaps in scientific knowledge remain.

Pain therapeutics market has been largely characterized by only incremental product innovation over the last decade, as most market segments continue to be dominated by long-established product categories, active pharmaceutical ingredients and concomitant mechanisms of action. Patent applications for novel pain therapeutics declined steadily in number from 4,970 in 2008 to 3,492 in 2012, an average annual decrease of 8%, as limited understanding of pain pathophysiology continues to hinder drug development in this arena.

The active pain pipeline is populated by 810 products across all stages of development, which exhibit a highly diverse range of molecular targets. It is identified that 129 first-in-class programs in active development, constituting 20% of the pipeline for which there is a disclosed molecular target, and acting on 80 first-in-class molecular targets.

Global pain treatment market is dominated by opioids and steroidal anti-inflammatory drugs, with no novel products currently able to challenge these products’ efficacy in treating moderate to severe acute pain. Furthermore, despite the significant unmet needs for more effective therapies in other pain subtypes, such as chronic and neuropathic pain, due to their rising prevalence, the factors underpinning these subtypes are complex and poorly understood.

The report “Frontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes” provides a brief analysis of innovation in the pain markets (including both nociceptive and neuropathic pain, of both a chronic and acute nature), in the context of the overall pipeline and current market landscape.

In depth, it provides the following:
  • Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.
  • Helps to identify and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.
  • Analysis of the deals landscape surrounding first-in-class products in pain, and highlights opportunities for in-licensing.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

1 Table of Contents

2 Executive Summary
2.1 Substantial Unmet Needs Remain in Core Therapy Types
2.2 Highly Diversified Range of Innovative Programs in Early Pipeline
2.3 Rich Pipeline Landscape with Numerous Investment Opportunities

3 The Case for Innovation
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Development Remains Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation
3.6 Research Report Guidance

4 Clinical and Commercial Landscape
4.1 Disease Overview
4.1.1 Chronic and Neuropathic Pain
4.1.2 Disease Pathophysiology
4.1.3 Diagnosis
4.1.4 Treatment Options
4.2 Overview of Marketed Products for Pain
4.2.1 Analgesic Product Categories
4.2.2 Molecular Type Analysis
4.2.3 Current Unmet Needs

5 Assessment of Pipeline Product Innovation in Chronic, Acute and Neuropathic Pain
5.1 Pain Pipeline by Molecule Type, Stage of Development and Molecular Target
5.2 Comparative Distribution of Programs between the Pain Market and Pipeline by Therapeutic Target Family
5.3 First-in-Class Pipeline Programs
5.4 First-in-Class and Established Pipeline Products by Pain Subtype
5.5 Table of All First-in-Class Pain Pipeline Products

6 Pain Pathophysiology and Innovation Alignment
6.1 The Complexity of Signaling Networks in the Central Nervous System
6.2 Matrix Assessment

7 First-in-Class Target and Pipeline Program Evaluation
7.1 Pipeline Programs Targeting Nerve Growth Factor and High Affinity Nerve Growth Factor Receptor
7.2 Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 16
7.3 Pipeline Programs Targeting Bradykinin B1 Receptor
7.4 Pipeline Programs Targeting Opioid Receptor-Like-1 Receptor
7.5 Pipeline Programs Targeting Purinoceptor 7
7.6 Pipeline Programs Targeting Metabotropic Glutamate Receptors 6 and 7
7.7 Pipeline Programs Targeting Calcitonin Gene-Related Peptide Type-1 Receptor

8 Deals and Strategic Consolidations
8.1 Industry-Wide First-in-Class Deals
8.2 Pain Deals Landscape
8.3 Licensing Deals
8.3.1 Molecule Type
8.3.2 Mechanism of Action
8.4 Co-development Deals
8.4.1 Molecule Type
8.4.2 Mechanism of Action
8.5 List of Pipeline Products without Prior Licensing or Co-Development Deal Involvement
9 Appendix
9.1 Abbreviations
9.2 References
9.3 Contact Us
9.4 Disclaimer

List of Tables
Table 1: Pain Market, Global, Categories of Pain, 2016
Table 2: Pain Market, Global, Data for Nerve Growth Factor as a Molecular Target, 2016
Table 3: Pain Market, Global, Data for High Affinity Nerve Growth Factor Receptor as a Molecular Target, 2016
Table 4: Pain Market, Global, Data for Tumor Necrosis Factor Receptor Superfamily Member 16 as a Molecular Target, 2016
Table 5: Pain Market, Global, Data for Bradykinin B1 Receptor as a Molecular Target, 2016
Table 6: Pain Market, Global, Data for Opioid Receptor-Like-1 Receptor as a Molecular Target, 2016
Table 7: Pain Market, Global, Data for Purinoceptor 7 as a Molecular Target, 2016
Table 8: Pain Market, Global, Data for Metabotropic Glutamate Receptor 6 as a Molecular Target, 2016
Table 9: Pain Market, Global, Data for Metabotropic Glutamate Receptor 7 as a Molecular Target, 2016
Table 10: Pain Market, Global, Data for Calcitonin Gene-Related Peptide Type-1 Receptor as a Molecular Target, 2016

List of Figures
Figure 1: Pharmaceutical Market, Global, Innovation Trends in Product Approvals, 1987-2012
Figure 2: Pharmaceutical Market, Global, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006-2013
Figure 3: Pain Market, Global, Treatment Algorithm
Figure 4: Pain Market, Global, WHO Analgesic Ladder
Figure 5: Pain Market, Global, Marketed Products by Molecule Type and Molecular Target, 2016
Figure 6: Pharmaceutical Market, Global, Developmental Pipeline Overview, 2016
Figure 7: Pain Market, Global, Developmental Pipeline Overview, 2016
Figure 8: Pain Market, Global, Developmental Pipeline Molecular Target Categories, 2016
Figure 9: Pain Market, Global, Molecular Target Category Comparison of Pipeline and Marketed Products, 2016
Figure 10: Pain Market, Global, Molecular Target Category Comparison of Pipeline First-in-Class and Established Molecular Targets, 2016
Figure 11: Pain Market, Global, Level of First-in-Class Innovation by Stage of Development (%), 2016
Figure 12: Pain Market, Global, Level of First-in-Class Innovation by Molecular Target (%), 2016
Figure 13: Pain Market, Global, Total Pipeline Products by Pain Subtype and Stage of Development, 2016
Figure 14: Pain Market, Global, Total Pipeline Products by Pain Subtype and Stage of Development, 2016
Figure 15: Pain Market, Global, First-in-Class Pipeline Products by Pain Subtype and Molecular Target, 2016
Figure 16: Pain Market, Global, First-in-Class Pipeline Products by Pain Subtype and Stage of Development, 2016
Figure 17: Pain Market, Global, First-in-Class Products in the Pipeline Part 1, 2016
Figure 18: Pain Market, Global, First-in-Class Products in the Pipeline Part 2, 2016
Figure 19: Pain Market, Global, First-in-Class Molecular Target Analysis Matrix Part 1, 2016
Figure 20: Pain Market, Global, First-in-Class Molecular Target Analysis Matrix Part 2, 2016
Figure 21: Pain Market, Global, Pipeline Programs Targeting Nerve Growth Factor, 2016
Figure 22: Pain Market, Global, Pipeline Programs Targeting High Affinity Nerve Growth Factor Receptor, 2016
Figure 23: Pain Market, Global, Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 16, 2016
Figure 24: Pain Market, Global, Pipeline Programs Targeting Bradykinin B1 Receptor, 2016
Figure 25: Pain Market, Global, Pipeline Programs Targeting Opioid Receptor-Like-1 Receptor, 2016
Figure 26: Pain Market, Global, Pipeline Programs Targeting Purinoceptor 7, 2016
Figure 27: Pain Market, Global, Pipeline Programs Targeting Glutamate Receptor 6, 2016
Figure 28: Pain Market, Global, Pipeline Programs Targeting Glutamate Receptor 7, 2016
Figure 29: Pain Market, Global, Pipeline Programs Targeting Calcitonin Gene-Related Peptide Type-1 Receptor, 2016
Figure 30: Pharmaceutical Market, Global, Industry-Wide Deals by Stage of Development, 2006-2014
Figure 31: Pharmaceutical Market, Global, Industry Licensing Deal Values by Stage of Development, 2006-2014
Figure 32: Pain Market, Global, Licensing Deals by Region and Value, 2006-2016
Figure 33: Pain Market, Global, Licensing Deals by Stage of Development and Value, 2006-2016
Figure 34: Pain Market, Global, Licensing Deals by Stage of Development and Molecule Type, 2006-2016
Figure 35: Pain Market, Global, Licensing Deals by Stage of Development and Molecular Target, 2006-2016
Figure 36: Pain Market, Global, Summary of Licensing Deals Valued Above $100m, 2006-2016
Figure 37: Pain Market, Global, Co-development Deals by Region and Value, 2006-2015
Figure 38: Pain Market, Global, Co-Development Deals by Stage of Development and Value, 2006-2016
Figure 39: Pain Market, Global, Co-Development Deals by Stage of Development and Molecule Type, 2006-2016
Figure 40: Pain Market, Global, Co-Development Deals by Stage of Development and Molecular Target, 2006-2016
Figure 41: Pain Market, Global, Summary of Co-development Deals Valued Above $100m, 2006-2016
Figure 42: Pain Market, Global, List of Pipeline Products With Prior Licensing or Co-Development Deal Involvement, 2016
Figure 43: Pain Market, Global, List of Pipeline Products Without Prior Licensing or Co-Development Deal Involvement, 2016 58

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Although opioids continue to dominate the chronic pain market, adverse events associated with the drug such as the potential for abuse mean the treatment space is rife with unmet needs, which is encouraging pharmaceutical companies to explore innovative alternatives to opioids.

Our latest report states that while opioids remain the most effective modes of treatment, their potential for abuse has yet to be addressed, and thus their effectiveness is limited in chronic pain conditions, as they cannot be used for prolonged durations.

One of the publishers analysts states that: “Moderate-to-severe pain has been and continues to be dominated by opioids, which are increasingly being reformulated to offer abuse resistance, whereas mild pain is effectively being treated with non-steroidal anti-inflammatory drugs (NSAID).

“However, significant unmet needs remain, as chronic pain subtypes - and particularly neuropathic pain - often do not respond well to existing therapies, which do not align well with the underlying molecular pathophysiological causes of pain.”

While the pain therapeutics pipeline is extremely large and diverse, it is characterized by a high overall historic clinical attrition rate for novel analgesics, and a low level of first-in-class innovation.

The active pain pipeline is populated by 810 products across all stages of development, which exhibit a highly diverse range of molecular targets. GBI Research’s analyses identified 129 first-in-class programs in active development, constituting 20% of the pipeline for which there is a disclosed molecular target, and acting on 80 first-in-class molecular targets.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll